TriSalus Life Sciences (TLSI) Share-based Compensation (2022 - 2026)

TriSalus Life Sciences' Share-based Compensation history runs 5 years deep, the most recent figure standing at $2.5 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 52.59% year-over-year to $2.5 million in Q1 2026; TTM through Mar 2026 was $10.0 million, a 67.08% increase from a year earlier, with the FY2025 full-year figure at $9.1 million, up 67.82% from the prior year.
• Share-based Compensation eased to $2.5 million in Q1 2026 per TLSI's latest filing, from $9.1 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $9.1 million in Q4 2025 and bottomed at -$3.5 million in Q3 2025.
• The 5-year median for Share-based Compensation is $744000.0 (2023), against an average of $1.2 million.
• Biggest YoY gain for Share-based Compensation was 1822.97% in 2024; the steepest drop was 571.89% in 2024.
• Year by year, Share-based Compensation stood at $117000.0 in 2022, then slumped by 443.59% to -$402000.0 in 2023, then soared by 1338.06% to $5.0 million in 2024, then surged by 83.46% to $9.1 million in 2025, then slumped by 72.93% to $2.5 million in 2026.
• Per Business Quant, the three latest TLSI Share-based Compensation figures stand at $2.5 million (Q1 2026), $9.1 million (Q4 2025), and -$3.5 million (Q3 2025).